The Biology of Cancer - Vibrational Spectroscopy for Tissue Analysis - page 53

39. Bishop, J. M., 1995. Cancer: The Rise of the Genetic Paradigm. Genes Development
9, 1309-1315.
40. Friedberg, E. C., 1986. Cancer Biology: Readings from Scientific American . New York:
W. H. Freeman.
41. Rotenberg, S. A., and Weinstein, I. B., 1991. Protein Kinase C in neoplastic cells.
In T. G. Pretlow and T. P. Pretlow, eds., Biochemical and Molecular Aspects of
Selected Cancers, Vol. 1 , 25-73. San Diego: Academic Press.
42. Bishop, J. M. 1987. The molecular genetics of cancer. Science 235, 305-311.
43. Slamon, D. J. 1987. Protooncogenes and human cancer. N. Engl. J. Med . 317,
955-957.
44. Hu, J., Cladel, N. M., Budgeon, L. R., and Christensen, N. D. 2004. Character-
ization of three rabbit oral papillomavirus oncogenes. Virology 325, 48-55.
45. Cid-Arregui, A., Juarez, V., and zur Hausen, H. 2003. A synthesis E7 gene of
human papillomavirus type 16 that yields enhanced expression of the protein
in mammalian cells and is useful for DNA immunization studies. Journal of
Virology 77, 4928-4937.
46. Embers, M. B., Budgeon, L. R, Pickel, M., and Christensen, N. D. 2002. Protective
immunity to rabbit oral and cutaneous papillomaviruses by immunization with
short peptides of 12, the minor capsid protein. Journal of Virology 76, 9798-9805.
47. Peh, W. L., Middleton, K., Christensen, N., et al. 2002. Life cycle heterogeneity in
animal models of human papillomavirus-associated disease. Journal of Virology
76, 10401-10416.
48. Nilsson, J. A., and Cleveland, J. L. 2003. Myc pathways provoking cell suicide
and cancer. Oncogenes 22, 9007-9021.
49. Sears, R. C. 2004. The life cycle of C-Myc: From synthesis to degradation. Cell
Cycle 3, 1133-1137.
50. Rimpi, S., and Nilsson, J. A. 2007. Metabolic enzymes regulated by the Myc onco-
gene are possible targets for chemotherapy or chemoprevention. Biochemical
Society Transactions 35(2), 305-310.
51. Askew, D. S., Ashmun, R. A., Simmonis, B. C., and Cleveland, J. I. 1991.
Constitutive C-Myc expression in an IL-3-dependent myeloid cell line sup-
presses cell cycle arrest and accelerates apoptosis. Oncogenes 6, 1915-1922.
52. Evan, G. I., Wyllie, A. H., Gilbert, C. S., et al. 1992. Cell 69, 119-128.
53. Druker B. J., Mamon H. J., and Roberts T. M. 1989. Oncogenes, growth factors,
and signal transduction. N. Engl. J. Med . 321(20), 1383-1391.
54. Knudson, A. G. 1993. Antioncogenes and human cancer. Proceedings of the
National Academy of Sciences USA 90, 10914-10921.
55. Knudson, A. G. 1971. Mutation and cancer: Statistical study of retinoblastoma.
Proceedings of the National Academy of Sciences USA 68, 820-823.
56. Pharoah P. D., Day N. E., and Caldas C. 1999. Somatic mutations in the p53 gene
and prognosis in breast cancer meta-analysis. British J. of Cancer 80, 1968-1973.
57. Horowitz J. M., Park S. H., Bogenmann E., et al. 1990. Frequent inactivation of
the retinoblastoma inactivation of the retinoblastoma antioncogene is restricted
to a subset of human tumour-cells. Proceedings of the National Academy of Sciences
USA 87, 2775-2779.
58. Friend S. H., Harowitz J. M., Gerber M. R., et al. 1987. Deletions of a DNA-
sequence in retinoblastoma and mesenchymal tumours: Organization of the
sequence and its encoded protein. Proceedings of the National Academy of Sciences
USA 84, 9059-9063.